[go: up one dir, main page]

AR032432A1 - Combinaciones oncoliticas para el tratamiento de cancer - Google Patents

Combinaciones oncoliticas para el tratamiento de cancer

Info

Publication number
AR032432A1
AR032432A1 ARP000105955A ARP000105955A AR032432A1 AR 032432 A1 AR032432 A1 AR 032432A1 AR P000105955 A ARP000105955 A AR P000105955A AR P000105955 A ARP000105955 A AR P000105955A AR 032432 A1 AR032432 A1 AR 032432A1
Authority
AR
Argentina
Prior art keywords
oncolitical
combinations
cancer treatment
ltb4
effectiveness
Prior art date
Application number
ARP000105955A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR032432A1 publication Critical patent/AR032432A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los antagonistas de leucotrieno (LTB4) mejoran la efectividad de agentes anti-cáncer de 2' û2' difluoronucleosido.
ARP000105955A 1999-11-11 2000-11-10 Combinaciones oncoliticas para el tratamiento de cancer AR032432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16478699P 1999-11-11 1999-11-11

Publications (1)

Publication Number Publication Date
AR032432A1 true AR032432A1 (es) 2003-11-12

Family

ID=22596085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105955A AR032432A1 (es) 1999-11-11 2000-11-10 Combinaciones oncoliticas para el tratamiento de cancer

Country Status (22)

Country Link
EP (1) EP1231938A2 (es)
JP (1) JP2003513916A (es)
KR (1) KR20020069512A (es)
CN (1) CN1390139A (es)
AR (1) AR032432A1 (es)
AU (1) AU778829B2 (es)
BR (1) BR0015490A (es)
CA (1) CA2391416A1 (es)
CZ (1) CZ20021551A3 (es)
EA (1) EA200200545A1 (es)
HK (1) HK1050132A1 (es)
HU (1) HUP0204449A3 (es)
IL (1) IL148579A0 (es)
MX (1) MXPA02004733A (es)
NO (1) NO20022245L (es)
NZ (1) NZ517667A (es)
PE (1) PE20010701A1 (es)
PL (1) PL355172A1 (es)
SK (1) SK6492002A3 (es)
TR (1) TR200201245T2 (es)
WO (1) WO2001034137A2 (es)
ZA (1) ZA200202822B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797723B1 (en) 1999-11-11 2004-09-28 Eli Lilly And Company Heterocycle substituted diphenyl leukotriene antagonists
AU1916601A (en) * 1999-11-11 2001-06-06 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) * 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
EP1326605A4 (en) * 2000-05-09 2004-03-17 Univ Creighton USE OF INHIBITORS OF THE BINDING OF LEUKOTRIEN B4 TO LEUKOTRIEN B4 RECEPTOR TO INHIBIT PROLIFERATION AND INDUCTION OF APOPTOSE IN CANCER CELLS
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
CN1302782C (zh) * 2005-01-17 2007-03-07 北京京卫燕康药物研究所有限公司 盐酸吉西他滨溶液型注射剂
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
US8044236B2 (en) 2006-10-12 2011-10-25 Institute Of Medicinal Molecular Design, Inc. Carboxilic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
BR112015009751A2 (pt) 2012-10-31 2017-07-11 Bayer Cropscience Ag novos compostos heterocíclicos como pesticidas
CN103319466B (zh) * 2013-07-04 2016-03-16 郑州大学 含香豆素母核的1,2,3-三唑-氨基二硫代甲酸酯化合物、制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation

Also Published As

Publication number Publication date
PE20010701A1 (es) 2001-07-07
NO20022245L (no) 2002-07-09
NO20022245D0 (no) 2002-05-10
TR200201245T2 (tr) 2004-08-23
WO2001034137A2 (en) 2001-05-17
NZ517667A (en) 2004-05-28
ZA200202822B (en) 2003-09-23
EA200200545A1 (ru) 2002-12-26
MXPA02004733A (es) 2002-08-30
KR20020069512A (ko) 2002-09-04
EP1231938A2 (en) 2002-08-21
WO2001034137A3 (en) 2002-02-14
HUP0204449A3 (en) 2006-02-28
HUP0204449A2 (hu) 2003-04-28
JP2003513916A (ja) 2003-04-15
CA2391416A1 (en) 2001-05-17
CN1390139A (zh) 2003-01-08
AU1599001A (en) 2001-06-06
HK1050132A1 (zh) 2003-06-13
SK6492002A3 (en) 2003-09-11
PL355172A1 (en) 2004-04-05
BR0015490A (pt) 2002-07-09
CZ20021551A3 (cs) 2003-02-12
AU778829B2 (en) 2004-12-23
IL148579A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AR032432A1 (es) Combinaciones oncoliticas para el tratamiento de cancer
DE69925133D1 (de) Pyrrolobenzodiazepine
DE60020812D1 (de) Heteroaryl-substituierte chinolin-2-on derivate verwendbar als antikrebsmittel
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
ITTO20000211A0 (it) Dispositivo combinatore di erogazione per l'alimentazione di apparecchi idraulici.
NO995823L (no) Terapeutisk middel for ereksjonsdysfunksjon
SE9903997D0 (sv) New compounds
SE9901077D0 (sv) Novel use
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
DE60112960D1 (de) Kondensierte pyridoindolderivate
SE9801494D0 (sv) Novel use
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
IT1319267B1 (it) Apparecchiatura per impedire la sfilacciatura di linee di cuciture.
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
WO2001034198A3 (en) Oncolytic combinations for the treatment of cancer
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
PE20010744A1 (es) Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2001034134A3 (en) Oncolytic combinations for the treatment of cancer
BR0017046A (pt) Uso de azóis para prevenção de câncer de pele
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs

Legal Events

Date Code Title Description
FB Suspension of granting procedure